title: Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes.
abstract: Despite the use of recommended antiplatelet treatment strategies, the presence of diabetes mellitus (DM) has been consistently associated with a higher risk of recurrent ischemic events in patients suffering an acute coronary syndrome. The high prevalence of DM patients presenting with low responsiveness to standard oral antiplatelet treatment regimens contributes to these impaired outcomes. This article provides an overview of the currently available oral antiplatelet agents, focusing on limitations of these therapies in DM patients, and evaluates new antithrombotic treatment strategies that may help overcome these limitations.
authors.affiliation: Heart Diseases Institute, Hospital Universitari de Bellvitge-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona 08907, Spain.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Ferreiro
authors.forename: Angel R
authors.initials: AR
authors.lastname: Cequier
authors.forename: Dominick J
authors.initials: DJ
authors.lastname: Angiolillo
mesh_terms: D054058:Acute Coronary Syndrome / Q000150:complications / Q000188:drug therapy*; D000284:Administration, Oral; D001241:Aspirin / Q000627:therapeutic use; D000077407:Cilostazol; D000077144:Clopidogrel; D048909:Diabetes Complications / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D013777:Tetrazoles / Q000627:therapeutic use; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077144:Clopidogrel; D000077407:Cilostazol; D013988:Ticlopidine; D001241:Aspirin